In 2022, Utah had the lowest death rate from cancer among all U.S. states with around 116 deaths per 100,000 population. The states with the highest cancer death rates at that time were Mississippi, Kentucky and West Virginia. This statistic shows cancer death rates in the United States in 2022, by state.

In 2022, Kentucky reported the highest cancer incidence rate in the United States, with around 512 new cases of cancer per 100,000 inhabitants. This statistic represents the U.S. states with the highest cancer incidence rates per 100,000 population in 2022.

The United States Cancer Statistics (USCS) online databases in WONDER provide cancer incidence and mortality data for the United States for the years since 1999, by year, state and metropolitan areas (MSA), age group, race, ethnicity, sex, childhood cancer classifications and cancer site. Report case counts, deaths, crude and age-adjusted incidence and death rates, and 95% confidence intervals for rates. The USCS data are the official federal statistics on cancer incidence from registries having high-quality data and cancer mortality statistics for 50 states and the District of Columbia. USCS are produced by the Centers for Disease Control and Prevention (CDC) and the National Cancer Institute (NCI), in collaboration with the North American Association of Central Cancer Registries (NAACCR). Mortality data are provided by the Centers for Disease Control and Prevention (CDC), National Center for Health Statistics (NCHS), National Vital Statistics System (NVSS).

It is estimated that in 2025 there will be a total of 226,650 new cases of lung and bronchus cancer in the United States. The highest number of these cases are estimated to be in the state of Florida. This statistic presents the estimated number of new lung and bronchus cancer cases in the United States in 2025, by state.

In 2022, Kentucky had the highest incidence of alcohol-associated cancer in the United States, with a rate of 145 per 100,000 people. This graph shows the rate of alcohol-related cancers per 100,000 people in the United States in 2022, by state.

This study aims to evaluate the feasibility of applying a method of estimating the incidence of cancer to regions of the state of São Paulo, Brazil, from real data (not estimated) and retrospectively comparing the results obtained with the official estimates. A method based on mortality and on the incidence to mortality (I/M) ration was used according to sex, age, and tumor location. In the I/M numerator, new cases of cancer were used from the population records of Jaú and São Paulo from 2006-2010; in the denominator, deaths from 2006-2010 in the respective areas, extracted from the national mortality system. The estimates resulted from the multiplication of I/M by the number of cancer deaths in 2010 for each region. Population data from the 2010 Demographic Census were used to estimate incidence rates. For the adjustment by age, the world standard population was used. We calculated the relative differences between the gross incidence rates estimated in this study and the official ones. Age-adjusted cancer incidence rates were 260.9/100,000 for men and 216.6/100,000 for women. Prostate cancer was the most common in males, whereas breast cancer was most common in females. Differences between the rates of this study and the official rates were 3.3% and 1.5% for each sex. The estimated incidence was compatible with the officially presented state profile, indicating that the application of real data did not alter the morbidity profile, while it did indicate different risk magnitudes. Despite the over-representativeness of the cancer registry with greater population coverage, the selected method proved feasible to point out different patterns within the state.

In 2023, there were **** deaths from breast cancer per 100,000 population in the state of South Dakota, the lowest of any state that year. This statistic shows the death rate from breast cancer in the U.S. in 2023, by state.

This submission includes publicly available data extracted in its original form. Please reference the Related Publication listed here for source and citation information "The United States Cancer Statistics (USCS) are the official federal statistics on cancer incidence from registries having high-quality data and cancer mortality statistics for 50 states and the District of Columbia. USCS are produced by the Centers for Disease Control and Prevention (CDC) and the National Cancer Institute (NCI)." [Quote from: https://wonder.cdc.gov/cancer.htm]>

Editor’s Choice

• Global Breast Cancer Market size is expected to be worth around USD 49.2 Bn by 2032 from USD 19.8 Bn in 2022, growing at a CAGR of 9.8% during the forecast period from 2022 to 2032.
• Breast cancer is the most common cancer among women worldwide. In 2020, there were about 2.3 million new cases of breast cancer diagnosed globally.
• Breast cancer is the leading cause of cancer-related deaths in women. In 2020, it was responsible for approximately 685,000 deaths worldwide.
• The survival rate of breast cancer has improved over the years. In the United States, the overall five-year survival rate of breast cancer is around 90%.
• The American Cancer Society recommends annual mammograms starting at age 40 for women at average risk.
• Although rare, breast cancer also occurs in men. Less than 1% of breast cancer cases are diagnosed in males.

(Source: WHO, American Cancer Society)

What are Cancer Statistics in US States?

The circled group of good survivors has genetic indicators of poor survivors (i.e. low ESR1 levels, which is typically the prognostic indicator of poor outcomes in breast cancer) – understanding this group could be critical for helping improve mortality rates for this disease. Why this group survived was quickly analysed by using the Outcome Column (here Event Death - which is binary - 0,1) as a Data Lens (which we term Supervised vs Unsupervised analyses).

How to use this dataset

• A network was built using only gene expression with 272 breast cancer patients (as rows), and 1570 columns.

• Metadata includes patient info, treatment, and survival.

• Each node is a group of patients similar to each other. Flares (left) represent sub-populations that are distinct from the larger population. (One differentiating factor between the two flares is estrogen expression (low = top flare, high = bottom flare)).

• A bottom flare is a group of patients with 100% survival. The top flare shows a range of survival – very poor towards the tip (red), and very good near the base (circled).

Acknowledgments

When we use this dataset in our research, we credit the authors as :

• License : CC BY 4.0.

• This data set is taken from https://query.data.world/s/yi422lv7mkhnydnt4ixrfujmoaglpk .

The main idea for uploading this dataset is to practice data analysis with my students, as I am working in college and want my student to train our studying ideas in a big dataset, It may be not up to date and I mention the collecting years, but it is a good resource of data to practice

Cervical cancer (CC) is a public health problem with a high disease burden and mortality in developing countries. In Brazil, areas with low human development index have the highest incidence rates of Brazil and upward temporal trend for this disease. The Northeast region has the second highest incidence of cervical cancer (20.47 new cases / 100,000 women). In this region, the mortality rates are similar to rates in countries that do not have a health system with a universal access screening program, as in Brazil. Thus, this study aimed to analyze the effects of age, period and birth cohorts on mortality from cervical cancer in the Northeast region of Brazil. Estimable functions predicted the effects of age, period and birth cohort. The average mortality rate was 10.35 deaths per 100,000 women during the period analyzed (1980–2014). The highest mortality rate per 100,000 women was observed in Maranhão (24.39 deaths), and the lowest mortality rate was observed in Bahia (11.24 deaths). According to the period effects, only the state of Rio Grande do Norte showed a reduction in mortality risk in the five years of the 2000s. There was a reduction in mortality risk for birth cohorts of women after the 1950s, except in Maranhão State, which showed an increasing trend in mortality risk for younger generations. We found that the high rates of cervical cancer mortality in the states of northeastern Brazil remain constant over time. Even after an increase in access to health services in the 2000s, associated with increased access to the cancer care network, which includes early detection (Pap Test), cervical cancer treatment and palliative care. However, it is important to note that the decreased risk of death and the mortality rates from CC among women born after the 1960s may be correlated with increased screening coverage, as well as increased access to health services for cancer treatment observed in younger women.

IntroductionSociodemographic disparities in genitourinary cancer-related mortality have been insufficiently studied, particularly across multiple cancer types. This study aimed to investigate gender, racial, and geographic disparities in mortality rates for the most common genitourinary cancers in the United States.MethodsMortality data for prostate, bladder, kidney, and testicular cancers were obtained from the Centers for Disease Control and Prevention (CDC) WONDER database between 1999 and 2020. Age-adjusted mortality rates (AAMRs) were analyzed by year, gender, race, urban–rural status, and geographic region using a significance level of p < 0.05.ResultsOverall, AAMRs for prostate, bladder, and kidney cancer declined significantly, while testicular cancer-related mortality remained stable. Bladder and kidney cancer AAMRs were 3–4 times higher in males than females. Prostate cancer mortality was highest in black individuals/African Americans and began increasing after 2015. Bladder cancer mortality decreased significantly in White individuals, Black individuals, African Americans, and Asians/Pacific Islanders but remained stable in American Indian/Alaska Natives. Kidney cancer-related mortality was highest in White individuals but declined significantly in other races. Testicular cancer mortality increased significantly in White individuals but remained stable in Black individuals and African Americans. Genitourinary cancer mortality decreased in metropolitan areas but either increased (bladder and testicular cancer) or remained stable (kidney cancer) in non-metropolitan areas. Prostate and kidney cancer mortality was highest in the Midwest, bladder cancer in the South, and testicular cancer in the West.DiscussionSignificant sociodemographic disparities exist in the mortality trends of genitourinary cancers in the United States. These findings highlight the need for targeted interventions and further research to address these disparities and improve outcomes for all populations affected by genitourinary cancers.

One woman in nine can expect to develop breast cancer during her lifetime and one in 25 will die from the disease. Statistically low incidences of breast cancer are found in Newfoundland and Labrador, the territories, and northern areas of most provinces. Otherwise, each province has one or more pockets of significantly high breast cancer incidence. These are often located in more southerly areas, but they do not seem to be restricted to either urban or rural areas alone. Breast cancer rates are a health status indicator. They can be used to help assess health conditions. Health status refers to the state of health of a person or group, and measures causes of sickness and death. It can also include people’s assessment of their own health.

Between 2017 and 2021, female breast cancer was the type of alcohol-associated cancer with the highest incidence in the United States, with a rate of nearly 130 per 100,000 people. This graph shows the rate of alcohol-related cancers per 100,000 people from 2017 to 2021 in the United States, by cancer type.

Between 2017 and 2021, Kentucky had the highest incidence of tobacco-associated cancer in the United States, with a rate of around 235 per 100,000 people. This graph shows the rate of tobacco-related cancers per 100,000 people from 2017 to 2021 in the United States, by state.

In 2021, Utah had the highest rate of skin cancer, with an estimated ** people out of 100,000 diagnosed with melanoma or another non-epithelial skin cancer. This statistic shows the incidence rate of skin cancer in the U.S. in 2021, by state, per 100,000 population.

In 2022, adults aged 80 to 84 years had the highest incidence of alcohol-associated cancer in the United States, with a rate of around 577 per 100,000 people. This graph shows the rate of alcohol-related cancers per 100,000 people in the United States in 2022, by age.

The leading causes of death in the United States are heart disease and cancer. However, in 2022, COVID-19 was the fourth leading cause of death in the United States, accounting for around six percent of all deaths that year. In 2022, there were around 45 deaths from COVID-19 per 100,000 population.

Cardiovascular disease

Deaths from cardiovascular disease are more common among men than women but have decreased for both sexes over the past few decades. Coronary heart disease accounts for the highest portion of cardiovascular disease deaths in the United States, followed by stroke and high blood pressure. The states with the highest death rates from cardiovascular disease include Oklahoma, Mississippi, and Alabama. Smoking tobacco, physical inactivity, poor diet, stress, and being overweight or obese are all risk factors for developing heart disease.

Cancer

Although cancer is the second leading cause of death in the United States, like deaths from cardiovascular disease, deaths from cancer have decreased over the last few decades. The highest death rates from cancer come from lung cancer for both men and women. Breast cancer is the second deadliest cancer for women, while prostate cancer is the second deadliest cancer for men. West Virginia, Mississippi, and Kentucky lead the nation with the highest cancer death rates.

Counts and age-standardized rate of gastric adenocarcinoma incidence per 100,000 and average annual percent change from 2000 to 2019 in the United States, by age, sex, and race.

ObjectiveTriple negative breast cancer (TNBC) is a more aggressive subtype resistant to conventional treatments with a poorer prognosis. This study was to update the status of TNBC and the temporal changes of its incidence rate in the US.MethodsWomen diagnosed with breast cancer during 2011–2019 were obtained from the National Program of Cancer Registries (NPCR) and Surveillance, Epidemiology and End Results (SEER) Program SEER*Stat Database which covers the entire population of the US. The TNBC incidence and its temporal trends by race, age, region (state) and disease stage were determined during the period.ResultsA total of 238,848 (or 8.8%) TNBC women were diagnosed during the study period. TNBC occurred disproportionally higher in women of Non-Hispanic Black, younger ages, with cancer at a distant stage or poorly/undifferentiated. The age adjusted incidence rate (AAIR) for TNBC in all races decreased from 14.8 per 100,000 in 2011 to 14.0 in 2019 (annual percentage change (APC) = −0.6, P = 0.024). Incidence rates of TNBC significantly decreased with APCs of −0.8 in Non-Hispanic White women, −1.3 in West and −0.7 in Northeastern regions. Women with TNBC at the age of 35–49, 50–59, and 60–69 years, and the disease at the regional stage displayed significantly decreased trends. Among state levels, Mississippi (20.6) and Louisiana (18.9) had the highest, while Utah (9.1) and Montana (9.6) had the lowest AAIRs in 2019. New Hampshire and Indiana had significant and highest decreases, while Louisiana and Arkansas had significant and largest increases in AAIR. In individual races, TNBC displayed disparities in temporal trends among age groups, regions and disease stages. Surprisingly, Non-Hispanic White and Hispanic TNBC women (0–34 years), and Non-Hispanic Black women (≥70 years) during the entire period, as well as Asian or Pacific Islander women in the South region had increased trends between 2011 and 2017.ConclusionOur study demonstrates an overall decreased trend of TNBC incidence in the past decade. Its incidence displayed disparities among races, age groups, regions and disease stages. Special attention is needed for a heavy burden in Non-Hispanic Black and increased trends in certain groups.